98 related articles for article (PubMed ID: 25211926)
1. [Experience of the use of drug urorec: efficacy and safety].
Kadiev RM; Derevianko TI
Urologiia; 2014; (3):44, 46-7. PubMed ID: 25211926
[TBL] [Abstract][Full Text] [Related]
2. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
3. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
4. [Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia].
Neĭmark AI; Nozdrachev NA
Urologiia; 2013; (4):47-8, 50-1. PubMed ID: 24159765
[TBL] [Abstract][Full Text] [Related]
5. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
Capitanio U; Salonia A; Briganti A; Montorsi F
Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
[TBL] [Abstract][Full Text] [Related]
6. [Optimum initial dose of silodosin for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia].
Wada N; Numata A; Yamaguchi S; Osanai H; Mori T; Hou K; Fujisawa M; Kaneko S; Kakizaki H
Hinyokika Kiyo; 2011 Jun; 57(6):297-302. PubMed ID: 21795831
[TBL] [Abstract][Full Text] [Related]
7. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
8. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S; Benzeroual KE
Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
[TBL] [Abstract][Full Text] [Related]
9. [Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].
Ogawa T; Uemura H; Sano F; Hoshino K; Kita K; Hayashi N; Kagota M; Murakami T; Makiyama K; Miyoshii Y; Nakaigawa N; Yao M; Shimura H; Furuhata A; Fujikawa N; Shioi K; Ueki T; Hara Y; Saitou K; Kawakami S; Satomi Y; Hattori Y; Teranishi J; Kondo K; Kishida T; Saito K; Noguchi K; Fuji H; Yamaguchi T; Kinoshita Y; Nomura S; Yoshida M; Sakai N; Terao H; Matsumoto T; Umemoto S; Ogo Y; Kobayashi K; Noguchi S; Asakura T; Kohdaira T; Iguchi K; Izumi K; Hirano M; Kanno H; Takahashi T; Nukui F; Mokuo Y; Muraoka K; Osada Y; Funahashi M; Kitami K; Sugiura S; Ohta J; Miura T; Ishibashi Y; Masuda M; Komiya A; Suwa Y; Hashiba T; Mitaka K; Kobayashi M; Ohsaka K; Futoshi T; Tsuchiya T; Iwasaki A; Yamashita Y; Matsuzaki J; Kubota Y
Hinyokika Kiyo; 2008 Dec; 54(12):757-64. PubMed ID: 19174997
[TBL] [Abstract][Full Text] [Related]
10. EFFICACY OF SILODOSIN (UROREC®) IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA: THE MAXIMUM DECREASE OF BLADDER OUTLET OBSTRUCTION INDEX.
Khamzin A; Frolov R
Georgian Med News; 2018 Mar; (276):18-23. PubMed ID: 29697376
[TBL] [Abstract][Full Text] [Related]
11. Silodosin for benign prostatic hyperplasia.
Cantrell MA; Bream-Rouwenhorst HR; Hemerson P; Magera JS
Ann Pharmacother; 2010 Feb; 44(2):302-10. PubMed ID: 20071497
[TBL] [Abstract][Full Text] [Related]
12. A meta-analysis of efficacy and safety of the new α1A-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH.
Wu YJ; Dong Q; Liu LR; Wei Q
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):79-84. PubMed ID: 22986578
[TBL] [Abstract][Full Text] [Related]
13. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Watanabe T; Ozono S; Kageyama S
J Int Med Res; 2011; 39(1):129-42. PubMed ID: 21672315
[TBL] [Abstract][Full Text] [Related]
14. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
[TBL] [Abstract][Full Text] [Related]
15. [Evolution of lower urinary tract symptoms under silodosin: factors influencing patients' satisfaction].
Descazeaud A; Davin JL; De La Taille A; Karsenty G; Kouri G; Zerbib M; Morris V; Allaert FA; Coloby P
Prog Urol; 2014 Mar; 24(3):196-202. PubMed ID: 24560210
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
[TBL] [Abstract][Full Text] [Related]
17. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
[TBL] [Abstract][Full Text] [Related]
18. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
19. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.
Marks LS; Gittelman MC; Hill LA; Volinn W; Hoel G
J Urol; 2009 Jun; 181(6):2634-40. PubMed ID: 19371887
[TBL] [Abstract][Full Text] [Related]
20. α-Blockers for benign prostatic hyperplasia: the new era.
Lepor H; Kazzazi A; Djavan B
Curr Opin Urol; 2012 Jan; 22(1):7-15. PubMed ID: 22080875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
